Mink reports first quarter 2024 results

New york, may 14, 2024 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the first quarter 2024. mink executives will host a conference call and webcast at 8:30 a.m. et to discuss the results and provide a corporate update.
INKT Ratings Summary
INKT Quant Ranking